Publicaciones en las que colabora con ENRIQUE ROMERO BOBILLO (21)

2011

  1. Visfatina en pacientes obesos, relación con factores de riesgo cardiovascular, un estudio tranversal

    Medicina Clinica, Vol. 137, Núm. 5, pp. 199-203

2010

  1. C358A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and insulin resistance in patients with diabetes mellitus type 2

    Diabetes Research and Clinical Practice, Vol. 88, Núm. 1, pp. 76-80

  2. C358A missense polymorphism of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) and visfatin levels in obese females

    International Journal of Obesity, Vol. 34, Núm. 3, pp. 511-515

  3. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women

    European Review for Medical and Pharmacological Sciences, Vol. 14, Núm. 9, pp. 759-763

  4. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients

    Nutricion Hospitalaria, Vol. 25, Núm. 2, pp. 275-279

  5. G1359A polymorphism of the cannabinoid receptor gene (CNR1) and insulin resistance in patients with diabetes mellitus type 2

    Nutricion Hospitalaria, Vol. 25, Núm. 1, pp. 34-38

  6. Interaction between tumor necrosis factor-α gene -308G/A promoter and leptin receptor gene Lys656Asn single-nucleotide polymorphisms: Effect on serum leptin concentrations

    Annals of Nutrition and Metabolism, Vol. 57, Núm. 2, pp. 89-94

  7. Lack of effect of a moderate hypocaloric diet on visfatin levels in morbid obese patients: Relationship with insulin resistance

    European Review for Medical and Pharmacological Sciences, Vol. 14, Núm. 12, pp. 1031-1036

  8. Polimorfismo C358A de la enzima «amida hidrolasa de ácidos grasos» y los niveles de adipocitoquinas en obesos mórbidos

    Endocrinologia y Nutricion, Vol. 57, Núm. 2, pp. 54-59

  9. Polymorphism Trp64Arg of beta 3 adrenoreceptor gene: Allelic frequencies and influence on insulin resistance in a multicenter study of Castilla-León

    Nutricion Hospitalaria, Vol. 25, Núm. 2, pp. 299-303

  10. Polymorphism ala54Thr of fatty acid-binding protein 2: Allelic frequencies and influence on cardiovascular risk factors in a multicenter study of castilla y leon

    Annals of Nutrition and Metabolism, Vol. 57, Núm. 3-4, pp. 163-168

  11. Relation of -55CT polymorphism of uncoupling protein 3 gene with fat mass and insulin resistance in morbidly obese patients

    Metabolism: Clinical and Experimental, Vol. 59, Núm. 4, pp. 608-612

  12. Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naïve diabetes obese patients

    Diabetes Research and Clinical Practice, Vol. 89, Núm. 2, pp. 110-114

  13. Serum visfatin concentrations are related to dietary intake in obese patients

    Annals of Nutrition and Metabolism, Vol. 57, Núm. 3-4, pp. 265-270

2009

  1. Ala54Thr polymorphism of fatty acid binding protein 2, role on insulin resistance and cardiovascular risk factors in presurgical morbid obesity patients

    Obesity Surgery, Vol. 19, Núm. 12, pp. 1691-1696

  2. Effect of omega-3 fatty-acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: An open study

    European Review for Medical and Pharmacological Sciences, Vol. 13, Núm. 1, pp. 51-55

  3. G1359A polimorfismo del receptor CB1 endocanabinoide (CNR1) en parámetros antropométricos y riesgo cardiovascular en pacientes con obesidad mórbida

    Nutricion Hospitalaria, Vol. 24, Núm. 6, pp. 688-692

2008

  1. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients

    Nutrition, Vol. 24, Núm. 6, pp. 517-521

2007

  1. Circulating adipocytokines in obese nondiabetic patients in relationship with cardiovascular risk factors, anthropometry and resting-energy expenditure

    Annals of Nutrition and Metabolism, Vol. 51, Núm. 5, pp. 416-420

  2. Influencia del polimorfismo G308A del factor de necrosis tumoral alfa en la resistencia a la insulina en pacientes obesos tras la pérdida de peso

    Medicina Clinica, Vol. 129, Núm. 11, pp. 401-404